drugset / Trial / NCT01147445

Phase I Study of ETEC Vaccine

NCT01147445 ↗

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to learn if a new candidate vaccine (dmLT) against ETEC (E. coli infection) is safe. This vaccine will be tested to see what effects it has on the body and the ability of the vaccine to help the body resist disease. Researchers want to find the highest dose of dmLT vaccine that can be given without causing severe side effects. Most E. coli bacteria are harmless to humans and can even be beneficial. However, some are harmful, and can cause diarrhea. About 32 healthy adults, ages 18-45, will participate in this study. This study will require volunteers to stay in the research facility for several nights. Participants will be assigned to receive 1 of 4 vaccine doses by mouth. Study procedures include: stool samples, blood samples, and documenting side effects. Participants will be involved in study related procedures for about 8 months.

Timeline

Start
2010-09-13
Primary completion
2012-06-08
Completion
2012-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject double-mutant LT Vaccine 5 ug Oral
Subject double-mutant LT Vaccine 25 ug Oral
Subject double-mutant LT Vaccine 50 ug Oral
Subject double-mutant LT Vaccine 100 ug Oral

Indications